Peunitory Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of warts, including plantar warts, flat warts, common warts, corns, and calluses.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage for the medication is 1 ml administered twice daily. This regimen should be maintained for a total duration of 15 days.

Healthcare professionals are advised to ensure proper preparation and administration techniques are followed to optimize therapeutic outcomes.

Contraindications

Use of this product is contraindicated in the following situations:

Pregnancy: The product should not be used if the patient is pregnant or attempting to become pregnant, due to potential risks to fetal development.

Skin Irritation: Discontinue use if irritation or redness occurs, worsens, or does not improve with continued application, as this may indicate an adverse reaction to the product.

Warnings and Precautions

For external use only. This product is flammable; therefore, it must be kept away from fire and flame. It is imperative to keep this product out of reach of children to prevent accidental ingestion or misuse.

Healthcare professionals should advise patients to avoid contact with the eyes. In the event of contact, it is essential to flush the eyes with plenty of cool water immediately. The product should not be swallowed; if ingestion occurs, medical attention should be sought promptly, or the Poison Control Center (1-800-222-1222) should be contacted.

Children should use this product only under adult supervision to ensure safe application. It is also important to avoid prolonged exposure to air during use, as the substance may dissolve and crystallize easily. Users are advised to recap the product immediately after each use to maintain its integrity.

The product should not be used if the cap is broken or missing, as this may compromise safety and efficacy. Additionally, individuals should discontinue use if they become pregnant or are attempting to become pregnant while using this product.

If irritation or redness occurs, worsens, or does not improve with continued use, it is recommended to stop using the product and consult a healthcare professional.

Side Effects

Patients using this product should be aware of several important warnings and precautions. The product is intended for external use only and is flammable; therefore, it should be kept away from fire and flame. It is crucial to keep the product out of reach of children and to avoid contact with the eyes. In the event of eye contact, patients should flush the eyes with plenty of cool water. The product should not be swallowed; if ingestion occurs, medical attention should be sought immediately, or the Poison Control Center should be contacted at 1-800-222-1222.

Children should use this product only under adult supervision. Patients are advised to avoid prolonged exposure to air during use, as the substance may dissolve and crystallize easily. It is recommended to recap the product immediately after each use and to refrain from using it if the cap is broken or missing.

In the event of adverse reactions, patients should discontinue use if they become pregnant or are attempting to become pregnant while using this product. Additionally, if irritation or redness occurs, worsens, or does not improve with continued use, patients should stop using the product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Peunitory Wart Remover (salicylic acid 40%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this product under adult supervision. It is important for caregivers to monitor the use of the product to ensure safety and efficacy in children.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients or those attempting to conceive while using this product should be aware of potential risks. The effects of this product on fetal outcomes have not been fully established. Therefore, it is recommended that women of childbearing potential discuss their treatment options with their healthcare provider to weigh the benefits and risks associated with continued use during pregnancy. Caution is advised, and alternative therapies may be considered if pregnancy occurs or is planned during treatment.

Lactation

There is no information available regarding the use of PEUNITORY WART REMOVER (salicylic acid 40% liquid) in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider this lack of data when advising lactating mothers on the use of this product.

Renal Impairment

There is no information available regarding renal impairment, including dosage adjustments, special monitoring, or safety considerations for patients with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of specific guidance when treating patients with renal impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on clinical judgment.

For further guidance, healthcare professionals may refer to established protocols for managing drug overdosage or consult a poison control center.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to store the product at room temperature and to avoid exposure to excessive heat above 37°C (99°F). Patients should be informed that skin discoloration may occur during or after the use of the product.

It is essential for healthcare providers to discuss the implications of pregnancy with patients. Patients should be instructed to inform their healthcare provider if they become pregnant or are trying to become pregnant while using this product.

Patients should be made aware of the potential for irritation or redness. They should be advised to discontinue use and consult their healthcare provider if irritation or redness occurs, worsens, or does not improve with continued use.

Healthcare providers should recommend that patients clean the affected area before application. Soaking the affected area in warm water for 5 minutes is optional but may be beneficial. Patients should be instructed to dip the provided brush into the liquid and apply it to the affected area, ensuring complete coverage. After application, patients should allow the product to dry.

Patients should be informed to repeat this process 2-3 times daily until the skin appears smooth. In more severe cases, patients may need to continue treatment for a longer duration, and they should be encouraged to practice patience and perseverance during the treatment period. It is important to communicate that the longest continuous use of the product should not exceed 12 weeks.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which should be referenced for accurate identification. It is essential to store the product at room temperature, ensuring that the temperature does not exceed 37°C (99°F) to maintain its integrity.

To preserve the quality of the product, it is crucial to recap immediately after each use. Prolonged exposure to air should be avoided, as this may lead to the substance dissolving and crystallizing. Additionally, the product should not be used if the cap is broken or missing, as this could compromise its safety and efficacy.

Additional Clinical Information

Patients should be informed that the product is for external use only and is flammable; it must be kept away from fire and flame. It should be stored at room temperature, avoiding excessive heat above 37°C (99°F). Patients are advised to keep the product out of reach of children and to supervise its use in children. Contact with eyes should be avoided; in case of contact, the eyes should be flushed with plenty of cool water. The product should not be swallowed, and if ingested, medical attention or contact with a Poison Control Center (1-800-222-1222) is necessary.

The recommended route of administration is topical, with a dosage of 1 ml applied twice daily for a supply of 15 days. Patients should avoid prolonged exposure to air during use, as the substance may dissolve and crystallize easily. It is important to recap the product immediately after each use and not to use it if the cap is broken or missing. Clinicians should also inform patients that skin discoloration may occur during or after use.

Drug Information (PDF)

This file contains official product information for Peunitory Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)